Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein
- 1 October 2021
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 27 (10) , 1-12
Abstract
Chronic myeloid leukemia (CML) is a pathological condition associated with the uncontrolled proliferation of white blood cells and respective loss of function. Imatinib was the first drug that could effectively treat this condition, but its use is hindered by the development of mutations of the BCR-ABL protein, which are the cause of resistance. Therefore, dasatinib and afatinib present similarities that can be explored to discover new molecules capable of overcoming the effects of imatinib. Afatinib exhibited electronic and docking behavior, indicating that a replacement with some minor modifications could design a new potential inhibitor. The amide group in each candidate is clearly of pharmacophoric importance, and it needs to concentrate a negative region. Sulfur group presents a good pharmacophoric profile, which was shown by dasatinib results, adding to the influence of the Met318 residue in the target protein active site configuration. This behavior suggests that the sulfur atom and other fragments that have an affinity for the methionine sidechain may provide a significant positive effect when present in TKI molecules such as afatinib or dasatinib.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (310071/2018-6)
- Fundação de Apoio à Pesquisa do Distrito Federal (0193.001642/2017)
This publication has 47 references indexed in Scilit:
- Afatinib: First Global ApprovalDrugs, 2013
- Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de Novo DesignJournal of the American Chemical Society, 2013
- BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcriptionBlood, 2011
- NF-κB suppresses ROS levels in BCR–ABL+ cells to prevent activation of JNK and cell deathOncogene, 2011
- DasatinibBioDrugs, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa Crystallographica Section D Structural Biology, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Overview of Rational Drug Design1999
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Membrane receptors with protein-tyrosine kinase activityBiochimie, 1987